Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals.

Neurobiology of aging·2026
Same author

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effect of Parity and β-Amyloid on Cognition and Hippocampal Volume in Postmenopausal Women.

Neurology·2026
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Plasma phosphorylated tau217 discordance with amyloid status in an ethnically diverse mixed memory clinic cohort.

Journal of the neurological sciences·2026
Same author

Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.

Communications medicine·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Niklas Mattsson-Carlgren1, Sebastian Palmqvist2, Kanta Horie3

  • 1Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Sweden, Lund, Sweden.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Plasma %p-tau217 can rule out amyloid positivity, while eMTBR-tau243 can help confirm Alzheimer's disease (AD) diagnosis. A two-step approach using both biomarkers shows promise for improved AD patient stratification.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Alzheimer's disease (AD) diagnosis can be supported by early core 1 biomarkers like plasma p-tau217.
  • Later core 2 biomarkers, such as plasma eMTBR-tau243, may increase confidence in AD's contribution to cognitive symptoms.
  • The combined diagnostic utility of plasma p-tau217 and eMTBR-tau243 for AD patient stratification remains unclear.

Purpose of the Study:

  • To evaluate the diagnostic performance of plasma %p-tau217 and eMTBR-tau243 in patients with cognitive symptoms.
  • To determine if eMTBR-tau243 can identify high neocortical tau-PET burden in %p-tau217 positive individuals.
  • To propose a diagnostic model combining both biomarkers for improved AD assessment.

Main Methods:

  • Analysis of plasma %p-tau217 and eMTBR-tau243 in 571 patients from the Swedish BioFINDER-2 study.
  • Patients included those with subjective cognitive decline, mild cognitive impairment, and dementia.
  • Clinical AD diagnosis was confirmed by amyloid and tau-PET positivity.

Main Results:

  • %p-tau217 positivity was observed in 61% of patients, while eMTBR-tau243 positivity was found in 34%.
  • Among %p-tau217 positive patients, eMTBR-tau243 demonstrated 81% accuracy in predicting clinical AD.
  • eMTBR-tau243 effectively identified high tau-PET load among %p-tau217 positive individuals with 87% accuracy.

Conclusions:

  • Plasma %p-tau217 is effective for ruling out amyloid positivity, while eMTBR-tau243 aids in confirming clinical AD.
  • A proposed two-step model involves initial %p-tau217 testing, followed by eMTBR-tau243 for %p-tau217 positive cases.
  • This combined biomarker approach can help differentiate asymptomatic AD pathology from AD causing cognitive impairment and identify high tau burden.